Scancell Holdings Plc (LON:SCLP)‘s stock had its “buy” rating reissued by Panmure Gordon in a research report issued to clients and investors on Monday. They currently have a GBX 68 ($0.84) price objective on the stock. Panmure Gordon’s price target suggests a potential upside of 315.27% from the stock’s previous close.

Scancell Holdings Plc (LON:SCLP) opened at 16.04 on Monday. The stock’s market cap is GBX 41.95 million. Scancell Holdings Plc has a 52-week low of GBX 12.00 and a 52-week high of GBX 25.90. The stock has a 50 day moving average price of GBX 16.86 and a 200 day moving average price of GBX 17.14.

About Scancell Holdings Plc

Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects.

Receive News & Ratings for Scancell Holdings Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell Holdings Plc and related companies with's FREE daily email newsletter.